| 1 |
Methodological index for non‐randomized studies ( MINORS ): development and validation of a new instrument
Karem Slim, Emile Nini, Damien Forestier et al. · ANZ Journal of Surgery
|
Sep 2003 |
7,649 |
| 2 |
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Roberto Salgado et al. · Annals of Oncology
Open access |
11 Sep 2014 |
3,221 |
| 3 |
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Deborah Ford et al. · The American Journal of Human Genetics
Open access |
Mar 1998 |
3,057 |
| 4 |
Breast cancer
Nadia Harbeck, Frederique Madeleine Penault-Llorca, Javier Cortés et al. · Nature Reviews Disease Primers
ReviewOpen access |
23 Sep 2019 |
3,056 |
| 5 |
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fátima Cardoso, Stella Kyriakides, Shinji Ohno et al. · Annals of Oncology
Open access |
22 May 2019 |
2,287 |
| 6 |
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Astrid Lièvre, Jean‐Baptiste Bachet, Delphine Le Corre et al. · Cancer Research
|
15 Apr 2006 |
2,241 |
| 7 |
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard J. Escudier, Anna Pluzanska, P. Koralewski et al. · The Lancet
|
Dec 2007 |
2,234 |
| 8 |
GATE: a simulation toolkit for PET and SPECT
S Jan et al. · Physics in Medicine and Biology
Open access |
9 Sep 2004 |
2,171 |
| 9 |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al. · The Lancet Oncology
|
9 Jul 2010 |
2,168 |
| 10 |
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso et al. · Annals of Oncology
Open access |
11 Oct 2016 |
2,075 |
| 11 |
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Elżbieta Senkus, Stella Kyriakides, Shinji Ohno et al. · Annals of Oncology
Open access |
27 Aug 2015 |
1,660 |
| 12 |
Removing Noise From Pyrosequenced Amplicons
Christopher Quince, Anders Lanzen, Russell J Davenport et al. · BMC Bioinformatics
Open access |
28 Jan 2011 |
1,619 |
| 13 |
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al. · The Lancet Oncology
Open access |
12 May 2014 |
1,518 |
| 14 |
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Fátima Cardoso et al. · Annals of Oncology
Open access |
23 Sep 2020 |
1,397 |
| 15 |
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Fátima Cardoso et al. · Annals of Oncology
Open access |
23 May 2018 |
1,202 |
| 16 |
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortés, Joyce O’Shaughnessy, David M. Loesch et al. · The Lancet
|
Mar 2011 |
1,110 |
| 17 |
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth Ann Mittendorf, Hong Zhang, Carlos H. Barrios et al. · The Lancet
Open access |
20 Sep 2020 |
1,099 |
| 18 |
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlési et al. · The Lancet
Open access |
15 Jan 2016 |
1,011 |
| 19 |
Final Results of the 94–01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx Carcinoma
Fabrice Denis, Pascal Garaud, É. Bardet et al. · Journal of Clinical Oncology
|
9 Dec 2003 |
902 |
| 20 |
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino, Erika Paige Hamilton, Sara M. Tolaney et al. · Journal of Clinical Oncology
|
24 Apr 2020 |
827 |
| 21 |
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourina
Shona A. Hendry et al. · Advances in Anatomic Pathology
Open access100 authors |
2 Aug 2017 |
816 |
| 22 |
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Torsten O. Nielsen et al. · JNCI Journal of the National Cancer Institute
Open access |
8 Dec 2020 |
780 |
| 23 |
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
François‐Clément Bidard et al. · Journal of Clinical Oncology
Open access |
18 May 2022 |
754 |
| 24 |
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona A. Hendry et al. · Advances in Anatomic Pathology
Open access100 authors |
2 Aug 2017 |
739 |
| 25 |
Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations
Sunil R. Lakhani et al. · JNCI Journal of the National Cancer Institute
|
5 Aug 1998 |
708 |
| 26 |
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
Martin Jean Schlumberger, Bogdan Catargi, Isabelle Borget et al. · New England Journal of Medicine
Open access |
2 May 2012 |
698 |
| 27 |
Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype
Sunil R. Lakhani et al. · Clinical Cancer Research
Open access |
15 Jul 2005 |
613 |
| 28 |
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Magali Olivier, Anita Langer√∏d, Patrizia Carrieri et al. · Clinical Cancer Research
|
15 Feb 2006 |
604 |
| 29 |
Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study
Pierre Soubeyran, Carine A. Bellera, Jean Goyard et al. · PLoS ONE
Open access |
11 Dec 2014 |
601 |
| 30 |
HER2 testing in gastric cancer: a practical approach
Josef Rüschoff, Wedad M. Hanna, Michael Bilous et al. · Modern Pathology
Open access |
6 Jan 2012 |
600 |
| 31 |
Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation
Y. Pointreau, P. Garaud, Sophie CHAPET et al. · JNCI Journal of the National Cancer Institute
|
24 Mar 2009 |
574 |
| 32 |
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Peter Schmid et al. · New England Journal of Medicine
Open access |
15 Sep 2024 |
544 |
| 33 |
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Fátima Cardoso et al. · Annals of Oncology
Open access |
19 Sep 2014 |
543 |
| 34 |
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
Laurent Arnould, M Gelly, Frederique Madeleine Penault-Llorca et al. · British Journal of Cancer
Open access |
2006 |
539 |
| 35 |
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
Corine Bertolotto et al. · Nature
100 authors |
18 Oct 2011 |
529 |
| 36 |
HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
Josef Rüschoff, Manfred Dietel, Gustavo Bruno Baretton et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
Open access |
27 Jul 2010 |
497 |
| 37 |
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
José Baselga, José Manuel Trigo, Jean Bourhis et al. · Journal of Clinical Oncology
|
12 Jul 2005 |
491 |
| 38 |
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
ABCTB Investigators et al. · Nature Genetics
Open access476 authors |
23 Oct 2017 |
477 |
| 39 |
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
Makoto Nishio, Fabrice Barlési, Howard West et al. · Journal of Thoracic Oncology
Open access |
16 Dec 2020 |
473 |
| 40 |
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
Maria Vittoria Dieci et al. · Seminars in Cancer Biology
Open access |
12 Oct 2017 |
444 |
| 41 |
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3
Marie-Claude Marchand et al. · International Journal of Cancer
|
11 Dec 1995 |
420 |
| 42 |
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Céline Lefèbvre et al. · PLoS Medicine
Open access |
27 Dec 2016 |
413 |
| 43 |
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
Padmanee Sharma, Russell Kent Pachynski, Vivek Narayan et al. · Cancer Cell
Open access |
10 Sep 2020 |
409 |
| 44 |
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer
Reinhard Büttner, John R. Gosney, Birgit Guldhammer Skov et al. · Journal of Clinical Oncology
|
20 Oct 2017 |
405 |
| 45 |
Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial
Jean‐Michel Constantin et al. · The Lancet Respiratory Medicine
Open access |
6 Aug 2019 |
402 |
| 46 |
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer
Mathilde Bayet‐Robert, Fabrice Kwiatowski, Marianne Leheurteur et al. · Cancer Biology & Therapy
Open access |
2010 |
398 |
| 47 |
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
Benjamin Lacas et al. · Radiotherapy and Oncology
ReviewOpen access105 authors |
27 Jan 2021 |
391 |
| 48 |
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk
Fergus J. Couch et al. · PLoS Genetics
Open access270 authors |
27 Mar 2013 |
391 |
| 49 |
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo et al. · The Lancet Oncology
|
7 Dec 2017 |
389 |
| 50 |
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial
Jean Bourhis et al. · The Lancet Oncology
|
18 Jan 2012 |
388 |